Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02676765 · ClinicalTrials.gov registry record · Phase 3
Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy
A Phase 3 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 58
- Enrollment target
NCT02676765 is a Phase 3 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 58 participants.
The verdict
NCT02676765, a Phase 3 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 58 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.
Interventions
- DRUG Placebo tablet
- DRUG allergen extract tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-06 |
| Est. Completion | 2018-01-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02676765
The ClinicalTrials.gov registry entry for NCT02676765 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo tablet is the first listed.
NCT02676765 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02676765 about?
NCT02676765 is a clinical study titled "Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy". The purpose of this study is to determine if sublingual allergen immunotherapy tablets work by inducing a state of desensitization in mast cells and basophils.
What is the current status of trial NCT02676765?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 58 participants. The study started on 2016-06. Estimated completion is 2018-01-18.
What interventions are being tested in trial NCT02676765?
The interventions under investigation include: Placebo tablet (DRUG), allergen extract tablet (DRUG).
Who is sponsoring clinical trial NCT02676765?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.